Increased risk of select glucocorticoid adverse events in dogs of higher body weight.

Autor:	Sri-Jayantha LS; Pittsburgh Veterinary Specialty & Emergency Center (PVSEC); 807 Camp Horne Road, Pittsburgh, Pennsylvania 15237, USA., Doornink MT; Pittsburgh Veterinary Specialty & Emergency Center (PVSEC); 807 Camp Horne Road, Pittsburgh, Pennsylvania 15237, USA., Urie BK; Pittsburgh Veterinary Specialty & Emergency Center (PVSEC); 807 Camp Horne Road, Pittsburgh, Pennsylvania 15237, USA.
Jazyk:	angličtina
Zdroj:	The Canadian veterinary journal = La revue veterinaire canadienne [Can Vet J] 2022 Jan; Vol. 63 (1), pp. 32-38.
Abstrakt:	There are limited data on glucocorticoid treatment in dogs. The purpose of this study was to investigate whether dogs of higher body weight experienced more adverse events when receiving glucocorticoid therapy. Data pertaining to glucocorticoid therapy was abstracted from the records of 61 dogs that were prescribed glucocorticoids for treatment of immune-mediated thrombocytopenia or hemolytic anemia from 2014 to 2019. The odds of developing muscle atrophy and polyphagia during therapy were increased by 30% for each 5 kg of additional body weight. Almost half of the dogs (44.3%) fluctuated > 15% from baseline weight during therapy. Dogs whose body condition scored as above ideal were at increased risk (odds ratio = 4.2) for being diagnosed with urinary tract infection. Our findings suggest that standard linear glucocorticoid dosing may place higher body weight dogs at increased risk of developing adverse events. Accelerated glucocorticoid tapering and/or alternative dosing schemes in dogs with higher body weights may be prudent in efforts to improve tolerance and client compliance. (Copyright and/or publishing rights held by the Canadian Veterinary Medical Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu